Skip to content

Psilocybin and psychedelic-assisted therapy: all studies

Page 7 of 26: studies 61 to 70 of 252, newest first. Back to the psilocybin and psychedelic-assisted therapy overview

Research

[Psilocybin in the setting of treatment-resistant unipolar depression: A case report].

L'Encephale May 23, 2025 Maroussia Dumenil, Gabriel Cordova, Wissam El-Hage 1 citation

Current antidepressants have shown certain limitations in the treatment of unipolar depression. Their long onset of action, interactions, and side effects are obstacles to achieving lasting remission of this prevalent, often chronic or recurrent, pathology. Faced with this clinical necessity, research efforts have intensified in recent years around psychedelic drugs, with a particular focus on...

Music and non-music approaches in psilocybin-assisted psychotherapy: The sound of silence

Journal of Psychedelic Studies May 15, 2025 Sara G. Gloeckler, Julien Thibault Lévesque, Alexandre Lehmann et al. 3 citations

Abstract Music is integral to Psilocybin-assisted psychotherapy (PAP), believed to enhance therapeutic outcomes by structuring experiences and facilitating emotional expression. However, the effects of conducting PAP without music are underexplored. This study examines the experiences of two breast cancer patients undergoing psilocybin therapy under Canada's compassionate access program,...

Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review

Journal of Psychopharmacology May 12, 2025 Clémentine Estric, Thomas Duron, Sarah Kabani et al. 10 citations

Psychedelics offer promising outcomes in psychiatry. However, the preparation of participants (set) and the environmental conditions of taking a psychedelic (setting) are not standardized. We describe the set and setting for therapeutic use of psychedelic drugs in people with psychiatric disorders. In this systematic review, articles were identified in the PubMed and Web of Science databases...

The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.

American Journal of Psychotherapy May 6, 2025 David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al. 7 citations

Psychedelic therapies are promising new treatment options in psychiatry. Including the use of physical touch as part of treatment is an area of debate. This study aimed to characterize the viewpoints of practitioners on the use of touch in psychedelic therapy. An anonymous survey was distributed via e-mail to the contacts listed on ClinicalTrials.gov for trials of psilocybin and lysergic acid...

Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis

The International Journal of Psychiatry in Medicine April 25, 2025 Damian Swieczkowski, Aleksander Kwaśny, Michal Pruc et al. 4 citations

Objective To evaluate psilocybin's efficacy in reducing depressive and anxiety symptoms in cancer patients based on randomized controlled trials (RCTs). Methods This systematic review and network meta-analysis (NMA) followed PRISMA and Cochrane Handbook guidelines. PubMed, Embase and Cochrane Library data up to July 2024 were analyzed. Two RCTs met the inclusion criteria. Changes in Beck...

DOI: 10.1177/00912174251337572 (opens in new tab) Major depressive disorder Palliative medicine Palliative psychiatry Rapid-acting antidepressants +5

Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review.

Palliative & Supportive Care April 22, 2025 Maria I Lapid, Sandeep R Pagali, Andrea L Randall et al. 9 citations

Psychological and existential distress is prevalent among patients with life-threatening cancer, significantly impacting their quality of life. Psilocybin-assisted therapy has shown promise in alleviating these symptoms. This systematic review aims to synthesize the evidence on the efficacy and safety of psilocybin in reducing cancer-related distress. We searched MEDLINE, APA PsycINFO, Cochrane...

Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care

Palliative Medicine Reports April 17, 2025 Michel Dorval, Sue-Ling Chang, Houman Farzin et al. 3 citations

Psilocybin-assisted psychotherapy represents a promising addition to palliative care interventions, potentially improving quality of life by addressing existential distress. Despite its safety and effectiveness, this therapy remains limited in Canada, underscoring the need for improved access to ease suffering from life-threatening illnesses. However, important questions remain regarding how to...

DOI: 10.1089/pmr.2024.0108 (opens in new tab) Psilocybin Palliative care Psychotherapist Hallucinogen

Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry April 2, 2025 Viktoriia Kurkova, Olga Winkler, Andrew J. Greenshaw et al.

This scoping review addresses the need to comprehensively explore the potential of psychedelic-assisted psychotherapy (PAP) to facilitate recovery from moral injury. Moral injury (MI), characterized by profound psychological distress arising from morally challenging experiences, has garnered increased attention as a complex mental health concern with significant functional sequelae, especially...

Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.

Cureus April 1, 2025 Ciara Mimms, Kassandra Sotelo, Abdul Saboor Khaliq 1 citation

This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-resistant depression (TRD). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted across PubMed, Scopus, and Web of Science for randomized controlled...

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étude

The Canadian Journal of Psychiatry March 25, 2025 Noah Chisamore, Erica Kaczmarek, Zoe Doyle et al. 1 citation

Objective: To compare changes in depression, anxiety, and suicidality symptoms after a single 25 mg oral dose of psilocybin between treatment-resistant depression participants not on antidepressants at screening to participants that discontinued antidepressant medications leading up to receiving psilocybin-assisted psychotherapy (PAP). Methods: Participants (n = 27) received at least one 25 mg...

DOI: 10.1177/07067437251328316 (opens in new tab) Treatment-resistant depression Depressive disorders Mood disorders Psilocybin-assisted psychotherapy +4